Alzheimer’s Therapeutics Market

Alzheimer’s Therapeutics Market Outlook 2031

The global Alzheimer’s therapeutics market size was valued at USD 4.05 Billion in 2022 and is likely reach to USD 20.90 Billion by 2031, expanding at a CAGR of 20% during the forecast period, 2023–2031. The growth of the market is attributed to the rising prevalence of the disease and increasing old-age population which is highly susceptible to the disease.

Get Free Sample Report

Alzheimer's is a memory loss disorder that is caused due to the degeneration of the brain cells. In general, the brain cells damage has resulted in failure of synaptic transmission or proper functioning of brain. This degeneration often causes dementia which is associated with constant deterioration of behavioral skills, thinking, along with social skills that disturbs a person's capability to function properly.

The early symptoms of the disorder include failing to recall past conversations or events, agitation, repetitive movements, depression, insomnia, anxiety, and loss of reasoning abilities. If the disease continues, it causes extreme memory weakening and impairment that make the patient unable to perform day tasks.

There is no cure for the disease but with medications the patients can live longer by reducing the speed of memory degeneration. The treatment improves the person’s ability to live better life for a short period of time.

As per the World Alzheimer statistics, approximately 50 million reports of Alzheimer’s were recorded in year 2019 globally. This report further stated that the number was likely to surpass 152 million by 2050.?

According to the World Health Organization (WHO), the Alzheimer’s disease is the most common type of dementia and nearly 50 million people are reported with dementia with 10 million every year worldwide. WHO says that the cases number is going to reach 82 million mark by 2030.

The COVID-19 pandemic outbreak has impacted the global economy due the lockdown conditions and travel restrictions around the world.

However, the Alzheimer’s disease market is positively impacted by the pandemic as a study conducted in the UK suggests that the patient with dementia is more vulnerable to death if contracted COVID-19. This boosted the research activities on Alzheimer’s treatment and discovery of novel drug treatment.

Market Trends, Drivers, Restraints, and Opportunities

• Rising pipeline drug development, investment in biomarkers for drug development, growing prevalence of chronic diseases, and inclining diagnostics development for early detection are major drivers of the market. 
• Increasing awareness among the population regarding the disease and high involvement of governments to increase the expansion of advanced therapeutic methods are pushing the market growth.
• Extensive research on the drug development as well as advancements in diagnostics techniques are propelling the market expansion.
• Expensive cost of the treatment and issues concerning side effects using therapeutic drugs are major restraints to the market growth.
• Extensive research for the development of innovative disease therapeutics and treatment devices are offering huge opportunities for the market growth.

Scope of Alzheimer’s Therapeutics Market Report

The report on the global Alzheimer’s therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Alzheimer’s Therapeutics Market Segment Insights

Cholinesterase inhibitors segment is expected to grow at a robust pace

Based on drugs class, the global Alzheimer’s therapeutics market is bifurcated into cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist. The cholinesterase inhibitors segment is expected to grow at a robust pace during the projected period attributed to the major high revenue generating drugs such as Donepezil, Exelon, and galantamine.

These drugs are considered to be highly effective and with good safety for the disease treatment The N-methyl-D-aspartate (NMDA) receptor antagonist segment, however, is estimated to exhibit a high revenue of the market in the near future owing to wide adoption of the drug due to enrichment of targeting proteins and monoclonal antibodies.

Get Free Sample Report

Alzheimer’s Therapeutics Market Regional Outlook

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the well-developed healthcare infrastructure and high prevalence of disease in the region.

Furthermore, high purchasing power of the population as well as favorable reimbursement policies are major propelling factors of the market. However, the market of Europe is anticipated to grow at a substantial rate due to the great incidence of the disease in the region.

However, the Asia Pacific market is projected to expand at a substantial CAGR during the forecast period. The key factors contributing to the regional market growth are high number of geriatric population, government initiatives, and growing purchasing power of a large number of the population in the region.

Get Free Sample Report

Segments

Drugs Class

• Cholinesterase Inhibitors
• N-methyl-D-aspartate Receptor Antagonist

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Pfizer, Inc.
• Janssen Pharmaceutical
• Novartis AG
• Eisai Co. Ltd.
• Eli Lilly and Company
• H. Lundbeck A/S
• AC Immune
• Merck & Co. Inc.
• TauRx Pharmaceuticals Ltd.
• Forest Laboratories
• Teva Pharmaceuticals Industries Ltd
• GE healthcare
• DiaGenic ASA
• Actavis plc.
• VTV Therapeutics
• Hoffman-La Roche Ltd.
• AstraZeneca
• Daiichi Sankyo Company Ltd.

Competitive Landscape

The key market players in the global Alzheimer’s therapeutics market are Pfizer, Inc.; Janssen Pharmaceutical; Novartis AG; Eisai Co. Ltd.; Eli Lilly and Company; H. Lundbeck A/S; AC Immune; Merck & Co. Inc.; TauRx Pharmaceuticals Ltd.; Forest Laboratories; Teva Pharmaceuticals Industries Ltd; GE healthcare; DiaGenic ASA; Actavis plc.; VTV Therapeutics; Hoffman-La Roche Ltd.; AstraZeneca; and Daiichi Sankyo Company Ltd.